Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
JCO Clinical Cancer Informatics|January 18, 2019
CancerLinQ: Origins, Implementation, and Future DirectionsSamuel M Rubinstein, Jeremy L Warner
JCO Clinical Cancer Informatics|January 29, 2020
Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen ContentSamuel M Rubinstein, Peter C Yang, Andrew J Cowan, et al.
The Annals of Applied Statistics|August 6, 2024
BUILDING A DOSE TOXO-EQUIVALENCE MODEL FROM A BAYESIAN META-ANALYSIS OF PUBLISHED CLINICAL TRIALSElizabeth A Sigworth, Samuel M Rubinstein, Jeremy L Warner, et al.
JAMA Network Open|December 14, 2019
Indication of Measures of Uncertainty for Statistical Significance in Abstracts of Published Oncology Trials: A Systematic Review and Meta-analysisSamuel M Rubinstein, Elizabeth A Sigworth, Shervin Etemad, et al.
Seminars in Radiation Oncology|September 2, 2019
The Evolving Use of Electronic Health Records (EHR) for ResearchEllen Kim, Samuel M Rubinstein, Kevin T Nead, et al.
Iscience|April 1, 2022
Development of a bayesian toxo-equivalence model between docetaxel and paclitaxelElizabeth A Sigworth, Samuel M Rubinstein, Sandip Chaugai, et al.
JCO Clinical Cancer Informatics|January 7, 2021
Chemotherapy Knowledge Base Management in the Era of Precision OncologySamuel M Rubinstein, Tarsheen Sethi, Neeta K Venepalli, et al.
BMJ Connections. Oncology|March 23, 2026
Trends in design of FDA registrational randomized clinical trials in hematology and oncology: a 20-year cohort studyCharles J Milrod, Aidan Petrovich, Wayne Liang, et al.
JCO Clinical Cancer Informatics|May 5, 2020
Efficient and Accurate Extracting of Unstructured EHRs on Cancer Therapy Responses for the Development of RECIST Natural Language Processing Tools: Part I, the CorpusYalun Li, Yung-Hung Luo, Jason A Wampfler, et al.
JAMA Network Open|April 13, 2022
Evaluation of Information Theoretic Network Meta-analysis to Rank First-Line Anticancer Regimens for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast CancerXuanyi Li, Alicia Beeghly-Fadiel, Suresh K Bhavnani, et al.
Pageof 18